Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32272850,zeta potential,A particle size (196.4 ± 10.05 nm) with smooth and spherical shape alongwith zeta potential (11.8 ± 0.91 mV) and drug-content (44.64 ± 2.91 µg/mg) was observed.,A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272850/),mv,11.8,5102,DB01222,Budesonide
,32272850,elution time,"BUD 0.75 min and 431.61/323.16 m/z whereas Fluticasone (IS) 1.16 min and 501.42/313.31 m/z, elution time and transition respectively.",A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272850/),min,1.16,5103,DB01222,Budesonide
,32272850,elution time,"BUD 0.75 min and 431.61/323.16 m/z whereas Fluticasone (IS) 1.16 min and 501.42/313.31 m/z, elution time and transition respectively.",A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272850/),[m] / [z],501.42,5104,DB01222,Budesonide
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,1.1,5548,DB01222,Budesonide
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,4.0,5549,DB01222,Budesonide
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,2.6,5550,DB01222,Budesonide
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,1.1,5551,DB01222,Budesonide
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,4.0,5552,DB01222,Budesonide
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,2.6,5553,DB01222,Budesonide
,3811967,t1/2 alpha,The drug was rapidly (t1/2 alpha = 0.062 hrs) and extensively distributed into tissues and organs (V beta = 20.3 l/kg and Vss = 9.4 l/kg).,Tissue distribution and fate of budesonide in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3811967/),h,0.062,8242,DB01222,Budesonide
,3811967,V beta,The drug was rapidly (t1/2 alpha = 0.062 hrs) and extensively distributed into tissues and organs (V beta = 20.3 l/kg and Vss = 9.4 l/kg).,Tissue distribution and fate of budesonide in the mouse. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3811967/),[l] / [kg],20.3,8243,DB01222,Budesonide
,3811967,Vss,The drug was rapidly (t1/2 alpha = 0.062 hrs) and extensively distributed into tissues and organs (V beta = 20.3 l/kg and Vss = 9.4 l/kg).,Tissue distribution and fate of budesonide in the mouse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3811967/),[l] / [kg],9.4,8244,DB01222,Budesonide
,3811967,elimination half-life (t1/2 beta,The short elimination half-life (t1/2 beta = 1.55 hrs) and high blood clearance (Cl = 9.04 l/hr/kg) demonstrated a rapid elimination of budesonide from the body.,Tissue distribution and fate of budesonide in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3811967/),h,1.55,8245,DB01222,Budesonide
,3811967,blood clearance (Cl,The short elimination half-life (t1/2 beta = 1.55 hrs) and high blood clearance (Cl = 9.04 l/hr/kg) demonstrated a rapid elimination of budesonide from the body.,Tissue distribution and fate of budesonide in the mouse. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3811967/),[l] / [h·kg],9.04,8246,DB01222,Budesonide
,3912192,plasma clearance,After i.v. administration the plasma clearance was 0.921/min and the apparent volume of distribution was 2.81/kg.,Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),1/[min],0.921,8913,DB01222,Budesonide
,3912192,apparent volume of distribution,After i.v. administration the plasma clearance was 0.921/min and the apparent volume of distribution was 2.81/kg.,Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),1/[kg],2.81,8914,DB01222,Budesonide
,3912192,time to reach the peak plasma level,"After nasal administration, the time to reach the peak plasma level was approximately 30 min, and the systemic availability was 102%.",Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),min,30,8915,DB01222,Budesonide
,3912192,systemic availability,"After nasal administration, the time to reach the peak plasma level was approximately 30 min, and the systemic availability was 102%.",Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),%,102,8916,DB01222,Budesonide
,10325704,systemic availability,"The systemic availability of budesonide was estimated to be 6.1% of the nominal dose (95% confidence intervals (CI), 4.6% to 8.1%) or 26.3% of the dose to subject (95% CI, 20.3% to 34.1%).",Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325704/),%,6.1,10195,DB01222,Budesonide
,10325704,systemic availability,"The systemic availability of budesonide was estimated to be 6.1% of the nominal dose (95% confidence intervals (CI), 4.6% to 8.1%) or 26.3% of the dose to subject (95% CI, 20.3% to 34.1%).",Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325704/),%,26.3,10196,DB01222,Budesonide
,10325704,clearance,"Budesonide clearance was 0.54 l/min (95% CI, 0.46 to 0.62), steady state volume of distribution 55 litres (95% CI, 45 to 68), and the terminal half life was 2.3 hours (95% CI, 2.0 to 2.6).",Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325704/),[l] / [min],0.54,10197,DB01222,Budesonide
,10325704,steady state volume of distribution,"Budesonide clearance was 0.54 l/min (95% CI, 0.46 to 0.62), steady state volume of distribution 55 litres (95% CI, 45 to 68), and the terminal half life was 2.3 hours (95% CI, 2.0 to 2.6).",Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325704/),l,55,10198,DB01222,Budesonide
,10325704,terminal half life,"Budesonide clearance was 0.54 l/min (95% CI, 0.46 to 0.62), steady state volume of distribution 55 litres (95% CI, 45 to 68), and the terminal half life was 2.3 hours (95% CI, 2.0 to 2.6).",Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10325704/),h,2.3,10199,DB01222,Budesonide
,28301431,hepatic,"The hepatic and intestinal extraction ratios for midazolam were 0.11 ± 0.06 and 0.64 ± 0.25, respectively; however, CYP3A4 activity was nearly 5-fold lower in our CD cohort compared with published data among healthy subjects.",CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301431/),,0.11,12020,DB01222,Budesonide
,28301431,in,"The hepatic and intestinal extraction ratios for midazolam were 0.11 ± 0.06 and 0.64 ± 0.25, respectively; however, CYP3A4 activity was nearly 5-fold lower in our CD cohort compared with published data among healthy subjects.",CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28301431/),,0.11,12021,DB01222,Budesonide
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14022,DB01222,Budesonide
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14023,DB01222,Budesonide
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14024,DB01222,Budesonide
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14025,DB01222,Budesonide
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14026,DB01222,Budesonide
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14027,DB01222,Budesonide
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],64,17873,DB01222,Budesonide
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],56,17874,DB01222,Budesonide
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],79,17875,DB01222,Budesonide
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],72,17876,DB01222,Budesonide
more,30981874,cell viability,The cell viability of A549 cell was more than 90% for CHO-CD-MOF-BUD as a result of the good biocompatibility of CD-MOF.,Nanoporous CD-MOF particles with uniform and inhalable size for pulmonary delivery of budesonide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981874/),%,90,20242,DB01222,Budesonide
,25629228,particle size,The mean particle size of the microspheres prepared was found to be 15.21 ± 1.32 µm.,"Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629228/),µm,15.21,22692,DB01222,Budesonide
,25629228,drug loading,"The drug loading and entrapment efficiency of the formulation were 17.78% ± 2.31% and 81.6% ± 5.42%, respectively.","Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629228/),%,17.78,22693,DB01222,Budesonide
,25629228,entrapment efficiency,"The drug loading and entrapment efficiency of the formulation were 17.78% ± 2.31% and 81.6% ± 5.42%, respectively.","Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25629228/),%,81.6,22694,DB01222,Budesonide
,17883883,oral bioavailability,Its oral bioavailability is poor (6.7%).,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),%,6.7,29050,DB01222,Budesonide
,17883883,Plasma half-life,Plasma half-life is estimated to be 3.9 to 4.6 hours.,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),h,3.9 to 4.6,29051,DB01222,Budesonide
,17883883,terminal half-life,"FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively).",A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),l,96,29052,DB01222,Budesonide
,17883883,terminal half-life,"FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively).",A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),h,1.6,29053,DB01222,Budesonide
,18541030,AUC(t),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,2.6,32252,DB01222,Budesonide
,18541030,AUC(t),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,2.2,32253,DB01222,Budesonide
,18541030,AUC(i),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,2.9,32254,DB01222,Budesonide
,18541030,AUC(i),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,2.4,32255,DB01222,Budesonide
,18541030,t(max),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,0.4,32256,DB01222,Budesonide
,18541030,t(max),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,0.4,32257,DB01222,Budesonide
,18541030,C(max)/AUC(i),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,0.3,32258,DB01222,Budesonide
,18541030,C(max)/AUC(i),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,0.3,32259,DB01222,Budesonide
,18541030,MRT,"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,5.0,32260,DB01222,Budesonide
,18541030,MRT,"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,4.5,32261,DB01222,Budesonide
,18541030,C(max),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,0.9,32262,DB01222,Budesonide
,18541030,C(max),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,0.7,32263,DB01222,Budesonide
,18541030,t(1/2),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,3.7,32264,DB01222,Budesonide
,18541030,t(1/2),"Pharmacokinetic parameters were comparable in terms of AUC(t) (2.6 +/- 1.5 vs 2.2 +/- 0.7), AUC(i) (2.9 +/- 1.5 vs 2.4 +/- 0.7), t(max) (0.4 +/- 0.1 vs 0.4 +/- 0.2), C(max)/AUC(i) (0.3 +/- 0.1 vs 0.3 +/- 0.0), and MRT (5.0 +/- 1.4 vs 4.5 +/- 0.6), but not in the case of C(max) (0.9 +/- 0.3 vs 0.7 +/- 0.2) and t(1/2) (3.7 +/- 1.8 vs 2.9 +/- 0.4).","Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18541030/),,2.9,32265,DB01222,Budesonide
,10930963,absorption half-life,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),min,10,41262,DB01222,Budesonide
,10930963,absorption half-life,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),min,11.3,41263,DB01222,Budesonide
,10930963,elimination half-lives,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),h,2.4,41264,DB01222,Budesonide
,10930963,elimination half-lives,"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h vs FP 7.8 h).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),h,7.8,41265,DB01222,Budesonide
,10930963,V/F ratio,"Consistent with previous reports of FP's higher volume of distribution (V) and lower systemic bioavailability (F), the V/F ratio was lower for BUD than FP (498 l vs 8100 l).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),l,498,41266,DB01222,Budesonide
,10930963,V/F ratio,"Consistent with previous reports of FP's higher volume of distribution (V) and lower systemic bioavailability (F), the V/F ratio was lower for BUD than FP (498 l vs 8100 l).",Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10930963/),l,8100,41267,DB01222,Budesonide
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,30.8,49510,DB01222,Budesonide
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,8.0,49511,DB01222,Budesonide
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,29.5,49512,DB01222,Budesonide
,12893646,lung deposition,The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day.,Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12893646/),%,7.6,49513,DB01222,Budesonide
,6705451,plasma t 1/2,"The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr.",Kinetics of the epimeric glucocorticoid budesonide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705451/),h,2.66,49773,DB01222,Budesonide
,6705451,distribution volume (V beta),"The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr.",Kinetics of the epimeric glucocorticoid budesonide. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705451/),l,425,49774,DB01222,Budesonide
,6705451,plasma clearance,"The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr.",Kinetics of the epimeric glucocorticoid budesonide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705451/),[l] / [h],117,49775,DB01222,Budesonide
,12069174,Pulmonary deposition,"Pulmonary deposition (mean +/- sd) of PSbud was 57+/-7% and 58+/-8% of the nominal dose at 25 and 50 L x min(-1), respectively.",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),%,58,57516,DB01222,Budesonide
,12069174,peak plasma budesonide levels,"Mean peak plasma budesonide levels were 4.7 (PSbud25), 4.0 (PSbud50), and 2.2 ng x ml(-1) (THbud60).",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),[ng] / [ml],4.7,57517,DB01222,Budesonide
,12069174,peak plasma budesonide levels,"Mean peak plasma budesonide levels were 4.7 (PSbud25), 4.0 (PSbud50), and 2.2 ng x ml(-1) (THbud60).",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),[ng] / [ml],4.0,57518,DB01222,Budesonide
,12069174,peak plasma budesonide levels,"Mean peak plasma budesonide levels were 4.7 (PSbud25), 4.0 (PSbud50), and 2.2 ng x ml(-1) (THbud60).",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),[ng] / [ml],2.2,57519,DB01222,Budesonide
,12069174,t(max),Median t(max) was 5 min after both PSbud inhalations compared to 20 min for Turbuhaler (P < 0.05).,Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),min,5,57520,DB01222,Budesonide
,12069174,t(max),Median t(max) was 5 min after both PSbud inhalations compared to 20 min for Turbuhaler (P < 0.05).,Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),min,20,57521,DB01222,Budesonide
,12069174,AUCs,"Mean AUCs were comparable after all inhalations, 5.1 (PSbud25), 5.9 (PSbud50), and 6.0 (THbud60) ng x h x ml(-1).",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),[h·ng] / [ml],5.1,57522,DB01222,Budesonide
,12069174,AUCs,"Mean AUCs were comparable after all inhalations, 5.1 (PSbud25), 5.9 (PSbud50), and 6.0 (THbud60) ng x h x ml(-1).",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),[h·ng] / [ml],5.9,57523,DB01222,Budesonide
,12069174,AUCs,"Mean AUCs were comparable after all inhalations, 5.1 (PSbud25), 5.9 (PSbud50), and 6.0 (THbud60) ng x h x ml(-1).",Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12069174/),[h·ng] / [ml],6.0,57524,DB01222,Budesonide
,7696451,Cmax,Cmax was 2.5 nmol/L (range: 0.9-4.5 nmol/L) and was attained in 1.5 h (range 1-3 h).,Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696451/),[nM] / [l],2.5,60454,DB01222,Budesonide
,16390349,C(max),Food significantly decreased C(max) values from 1429 +/- 1014 to 1040 +/- 601 pg mL(-1) (P = 0.028) and AUC values from 14 814 +/- 11 254 to 13 486 +/- 9369 pg h(-1) mL(-1) (P = 0.008).,"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390349/),[pg] / [ml],1429,65914,DB01222,Budesonide
,16390349,C(max),Food significantly decreased C(max) values from 1429 +/- 1014 to 1040 +/- 601 pg mL(-1) (P = 0.028) and AUC values from 14 814 +/- 11 254 to 13 486 +/- 9369 pg h(-1) mL(-1) (P = 0.008).,"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390349/),[pg] / [ml],1040,65915,DB01222,Budesonide
,16390349,AUC,Food significantly decreased C(max) values from 1429 +/- 1014 to 1040 +/- 601 pg mL(-1) (P = 0.028) and AUC values from 14 814 +/- 11 254 to 13 486 +/- 9369 pg h(-1) mL(-1) (P = 0.008).,"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390349/),[pg] / [h·ml],14 814,65916,DB01222,Budesonide
,16390349,AUC,Food significantly decreased C(max) values from 1429 +/- 1014 to 1040 +/- 601 pg mL(-1) (P = 0.028) and AUC values from 14 814 +/- 11 254 to 13 486 +/- 9369 pg h(-1) mL(-1) (P = 0.008).,"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390349/),[pg] / [h·ml],13 486,65917,DB01222,Budesonide
,33523774,extraction recoveries,"With the assay, linear calibration curves were obtained over the concentration range of 10-1200 pg/mL for budesonide, with considerable extraction recoveries (84.7-89.4%), and negligible matrix effects (<4.1).",A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33523774/),%,84.7-89.4,67917,DB01222,Budesonide
,12492736,AUC0-24 h,Systemic exposure to budesonide (AUC0-24 h) after 1 week of oral administration was 41 +/- 21 nmol/L x h (mean +/- s.d.) in children and 35 +/- 20 nmol/L x h in adults.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),[nM] / [h·l],41,71529,DB01222,Budesonide
,12492736,AUC0-24 h,Systemic exposure to budesonide (AUC0-24 h) after 1 week of oral administration was 41 +/- 21 nmol/L x h (mean +/- s.d.) in children and 35 +/- 20 nmol/L x h in adults.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),[nM] / [h·l],35,71530,DB01222,Budesonide
,12492736,systemic availability,The estimated systemic availability in children was 9 +/- 5% and in adults 11 +/- 7%.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),%,9,71531,DB01222,Budesonide
,12492736,systemic availability,The estimated systemic availability in children was 9 +/- 5% and in adults 11 +/- 7%.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),%,11,71532,DB01222,Budesonide
,32762829,flow rate,"The HPLC assay was performed isocratically on a reversed-phase C18 μ-Bondapack column using a mobile phase of acetonitrile:water (45:55, v/v) at a flow rate of 1.2 mL/min, and the analytes were detected at 230 nm.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),[ml] / [min],1.2,71765,DB01222,Budesonide
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,10.94,71766,DB01222,Budesonide
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,12.4,71767,DB01222,Budesonide
,32762829,retention times,"The retention times for docetaxel, paclitaxel, and celecoxib were 10.94, 12.4, and 16.81 min, respectively.",Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32762829/),min,16.81,71768,DB01222,Budesonide
,10933104,inhaled flow rates,"The ASTA Medica multi-dose dry powder inhaler (AM-MDPI) has been designed to offer low resistance on inhalation, so that asthmatic patients can achieve inhaled flow rates of approximately 90 L x min(-1).",Scintigraphic comparison of budesonide deposition from two dry powder inhalers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933104/),[l] / [min],90,73920,DB01222,Budesonide
,10933104,flow rate,"At the lowest flow rate of 54 L x min(-1), comparable to that for the Turbuhaler (58 L x min(-1)), a similar percentage of the metered dose was delivered to the lung (AM-MDPI median 19.9%; Turbuhaler median 21.4%).",Scintigraphic comparison of budesonide deposition from two dry powder inhalers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933104/),[l] / [min],54,73921,DB01222,Budesonide
,10933104,flow rate,"At the lowest flow rate of 54 L x min(-1), comparable to that for the Turbuhaler (58 L x min(-1)), a similar percentage of the metered dose was delivered to the lung (AM-MDPI median 19.9%; Turbuhaler median 21.4%).",Scintigraphic comparison of budesonide deposition from two dry powder inhalers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933104/),[l] / [min],58,73922,DB01222,Budesonide
,10933104,peak inspiratory flow rate,"At high flow rate (peak inspiratory flow rate 99 L x min(-1)) the AM-MDPI delivered significantly more drug to the lung (median 32.1% of metered dose) than at 65 L x min(-1) or 54 L x min(-1) (median 25.0% and 19.9% of metered dose, respectively), thus demonstrating flow rate dependence.",Scintigraphic comparison of budesonide deposition from two dry powder inhalers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933104/),[l] / [min],99,73923,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],811.8,74209,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],1748,74210,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],224.3,74211,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],459.3,74212,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],1250,74213,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],2510,74214,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],315.4,74215,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],626.4,74216,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],27.20-29.40,74217,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],4.884-5.674,74218,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],69.49-77.08,74219,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],11.30-13.12,74220,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],46.49-53.58,74221,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],9.651-10.62,74222,DB01222,Budesonide
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],81.94-85.32,74223,DB01222,Budesonide
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],16.13-17.71,74224,DB01222,Budesonide
<,29237390,friability,Fluidized bed processor enabled the production of spherical and uniformly distributed pellets with optimum angle of repose (12-19°) and friability (<1%).,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),%,1,76425,DB01222,Budesonide
,29237390,Cmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),[ng] / [ml],380,76426,DB01222,Budesonide
,29237390,Cmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),[ng] / [ml],162,76427,DB01222,Budesonide
,29237390,Tmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),h,5,76428,DB01222,Budesonide
,29237390,Tmax,Promised pharmacokinetics was resulted as Cmax of 380ng/ml for BMP-2 and 162ng/ml for BMPP-5 and Tmax of 5 hr for BMP-2 and 12hr for BMPP-5.,Chronopharmacokinetic Evaluation of Budesonide Multiparticulate Systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29237390/),h,12,76429,DB01222,Budesonide
,26541989,relative absorption,"In pharmacokinetic studies, the mean relative absorption of budesonide in the region between the ascending colon and the descending/sigmoid colon was 95.9 %.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),%,95.9,82651,DB01222,Budesonide
,26541989,time,"A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),year,>,82652,DB01222,Budesonide
,26541989,time,"A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),year,1,82653,DB01222,Budesonide
,26541989,time,"A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed.",Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26541989/),d,181,82654,DB01222,Budesonide
less,30048776,limited absorption time,"Following deposited in rat airways, the drug particles underwent rapid dissolution and mucociliary clearance, leading to the complete removal of drugs from the airways within 2 h and a limited absorption time less than 2 h.",Ciclesonide and budesonide suspensions for nebulization delivery: An in vivo inhalation biopharmaceutics investigation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048776/),h,2,83682,DB01222,Budesonide
,19249257,flow-rate,The flow-rate was 1.00 ml/min.,Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),[ml] / [min],1.00,90663,DB01222,Budesonide
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,489.3,90664,DB01222,Budesonide
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,357.3,90665,DB01222,Budesonide
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,463.3,90666,DB01222,Budesonide
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,403.2,90667,DB01222,Budesonide
,23569029,Tlag,"The 9 mg Uceris® and 9 mg Entocort® EC formulations had comparable area under the concentration-time curve (AUC) data, but 9 mg Uceris® had a notably longer time to first appearance in plasma (median Tlag, 6 h versus 1 h, respectively), and a delayed time to maximum concentration (median Tmax, 15 h versus 5 h, respectively) compared with 9 mg Entocort® EC.",Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23569029/),h,6,91319,DB01222,Budesonide
,23569029,Tlag,"The 9 mg Uceris® and 9 mg Entocort® EC formulations had comparable area under the concentration-time curve (AUC) data, but 9 mg Uceris® had a notably longer time to first appearance in plasma (median Tlag, 6 h versus 1 h, respectively), and a delayed time to maximum concentration (median Tmax, 15 h versus 5 h, respectively) compared with 9 mg Entocort® EC.",Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23569029/),h,1,91320,DB01222,Budesonide
,23569029,Tmax,"The 9 mg Uceris® and 9 mg Entocort® EC formulations had comparable area under the concentration-time curve (AUC) data, but 9 mg Uceris® had a notably longer time to first appearance in plasma (median Tlag, 6 h versus 1 h, respectively), and a delayed time to maximum concentration (median Tmax, 15 h versus 5 h, respectively) compared with 9 mg Entocort® EC.",Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23569029/),h,15,91321,DB01222,Budesonide
,23569029,Tmax,"The 9 mg Uceris® and 9 mg Entocort® EC formulations had comparable area under the concentration-time curve (AUC) data, but 9 mg Uceris® had a notably longer time to first appearance in plasma (median Tlag, 6 h versus 1 h, respectively), and a delayed time to maximum concentration (median Tmax, 15 h versus 5 h, respectively) compared with 9 mg Entocort® EC.",Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23569029/),h,5,91322,DB01222,Budesonide
,12602671,bioavailability,"In this first study of the bioavailability of budesonide inhalation suspension in adults, there were no differences between nebulizers in lung deposition (14 to 16%) or systemic availability (15 to 17%) relative to the nominal budesonide dose.",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,14 to 16,91890,DB01222,Budesonide
,12602671,lung deposition,"In this first study of the bioavailability of budesonide inhalation suspension in adults, there were no differences between nebulizers in lung deposition (14 to 16%) or systemic availability (15 to 17%) relative to the nominal budesonide dose.",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,14 to 16,91891,DB01222,Budesonide
,12602671,systemic availability,"In this first study of the bioavailability of budesonide inhalation suspension in adults, there were no differences between nebulizers in lung deposition (14 to 16%) or systemic availability (15 to 17%) relative to the nominal budesonide dose.",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,15 to 17,91892,DB01222,Budesonide
,12602671,lung deposition,"Relative to the actual dose inhaled (dose-to-subject), lung deposition and systemic availability were statistically significantly higher for the Jet Plus (58 and 63%, respectively) and MA-2 (59 and 64%, respectively) nebulizers than the Inhalierboy (36 and 44%, respectively).",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,58,91893,DB01222,Budesonide
,12602671,lung deposition,"Relative to the actual dose inhaled (dose-to-subject), lung deposition and systemic availability were statistically significantly higher for the Jet Plus (58 and 63%, respectively) and MA-2 (59 and 64%, respectively) nebulizers than the Inhalierboy (36 and 44%, respectively).",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,59,91894,DB01222,Budesonide
,12602671,lung deposition,"Relative to the actual dose inhaled (dose-to-subject), lung deposition and systemic availability were statistically significantly higher for the Jet Plus (58 and 63%, respectively) and MA-2 (59 and 64%, respectively) nebulizers than the Inhalierboy (36 and 44%, respectively).",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,64,91895,DB01222,Budesonide
,12602671,lung deposition,"Relative to the actual dose inhaled (dose-to-subject), lung deposition and systemic availability were statistically significantly higher for the Jet Plus (58 and 63%, respectively) and MA-2 (59 and 64%, respectively) nebulizers than the Inhalierboy (36 and 44%, respectively).",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,36,91896,DB01222,Budesonide
,12602671,lung deposition,"Relative to the actual dose inhaled (dose-to-subject), lung deposition and systemic availability were statistically significantly higher for the Jet Plus (58 and 63%, respectively) and MA-2 (59 and 64%, respectively) nebulizers than the Inhalierboy (36 and 44%, respectively).",Systemic availability and lung deposition of budesonide via three different nebulizers in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12602671/),%,44,91897,DB01222,Budesonide
,10518844,total systemic availability,"In children 3 to 6 years of age, total systemic availability of budesonide after dosing with a jet nebulizer was approximately 6% of the labeled dose.",Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518844/),%,6,101815,DB01222,Budesonide
,10518844,volume of distribution at steady state,"In children 3 to 6 years of age, the volume of distribution at steady state of budesonide inhalation suspension is approximately 3 L/kg, with a terminal elimination half-life of 2.3 hours; systemic clearance is approximately 30 mL/kg.",Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518844/),[l] / [kg],3,101816,DB01222,Budesonide
,10518844,terminal elimination half-life,"In children 3 to 6 years of age, the volume of distribution at steady state of budesonide inhalation suspension is approximately 3 L/kg, with a terminal elimination half-life of 2.3 hours; systemic clearance is approximately 30 mL/kg.",Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518844/),h,2.3,101817,DB01222,Budesonide
,10518844,systemic clearance,"In children 3 to 6 years of age, the volume of distribution at steady state of budesonide inhalation suspension is approximately 3 L/kg, with a terminal elimination half-life of 2.3 hours; systemic clearance is approximately 30 mL/kg.",Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518844/),[ml] / [kg],30,101818,DB01222,Budesonide
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB01222,Budesonide
,8857075,systemic availability,Mean systemic availability was 16% (range 4.2-43%) and 15% (3.2-50%) after rectal administration and 6.3% (2.4-10%) after oral administration.,Rectal pharmacokinetics of budesonide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),%,16,102583,DB01222,Budesonide
,8857075,systemic availability,Mean systemic availability was 16% (range 4.2-43%) and 15% (3.2-50%) after rectal administration and 6.3% (2.4-10%) after oral administration.,Rectal pharmacokinetics of budesonide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),%,15,102584,DB01222,Budesonide
,8857075,systemic availability,Mean systemic availability was 16% (range 4.2-43%) and 15% (3.2-50%) after rectal administration and 6.3% (2.4-10%) after oral administration.,Rectal pharmacokinetics of budesonide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),%,6.3,102585,DB01222,Budesonide
,8857075,Cmax,"Cmax was 3.3 nmol center dot l-1 (0.95-8.2), 3.0 nmol center dot l-1 (0.64%-8.9) and 1.3 nmol center dot l-1 (0.61-3.0), respectively, for the three formulations.",Rectal pharmacokinetics of budesonide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),[center·dot·nM] / [l],3.3,102586,DB01222,Budesonide
,8857075,Cmax,"Cmax was 3.3 nmol center dot l-1 (0.95-8.2), 3.0 nmol center dot l-1 (0.64%-8.9) and 1.3 nmol center dot l-1 (0.61-3.0), respectively, for the three formulations.",Rectal pharmacokinetics of budesonide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),[center·dot·nM] / [l],3.0,102587,DB01222,Budesonide
,8857075,Cmax,"Cmax was 3.3 nmol center dot l-1 (0.95-8.2), 3.0 nmol center dot l-1 (0.64%-8.9) and 1.3 nmol center dot l-1 (0.61-3.0), respectively, for the three formulations.",Rectal pharmacokinetics of budesonide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),[center·dot·nM] / [l],1.3,102588,DB01222,Budesonide
,8857075,tmax,"Absorption was rapid and essentially terminated within 3 h after rectal dosing [tmax = 1.3 h for both formulations (range 0.5-2.0)], but was slower after oral dosing [tmax = 2.1 h (1.0-6.0)].",Rectal pharmacokinetics of budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),h,1.3,102589,DB01222,Budesonide
,8857075,tmax,"Absorption was rapid and essentially terminated within 3 h after rectal dosing [tmax = 1.3 h for both formulations (range 0.5-2.0)], but was slower after oral dosing [tmax = 2.1 h (1.0-6.0)].",Rectal pharmacokinetics of budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857075/),h,2.1,102590,DB01222,Budesonide
,12468958,time to peak plasma concentration,"The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),h,4.5,103399,DB01222,Budesonide
,12468958,time to peak plasma concentration,"The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),h,1.8,103400,DB01222,Budesonide
,12468958,time to peak plasma concentration,"The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),h,5.2,103401,DB01222,Budesonide
,12468958,time to peak plasma concentration,"The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),h,2.9,103402,DB01222,Budesonide
,12468958,areas under the plasma concentration curves,"However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),[nM] / [l],18.0,103403,DB01222,Budesonide
,12468958,areas under the plasma concentration curves,"However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),[nM] / [l],18.0,103404,DB01222,Budesonide
,12468958,areas under the plasma concentration curves,"However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),[nM] / [l],16.9,103405,DB01222,Budesonide
,12468958,areas under the plasma concentration curves,"However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l).","Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12468958/),[nM] / [l],18.5,103406,DB01222,Budesonide
,25228411,LOD,The measuring range was 50-5000 pg/mL with and LOD 24 pg/mL.,Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228411/),[pg] / [ml],24,107570,DB01222,Budesonide
,25228411,absolute recovery,The absolute recovery over the sample preparation procedure was estimated to 67%.,Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228411/),%,67,107571,DB01222,Budesonide
<,25228411,Total imprecision,Total imprecision was <9% at three levels and accuracy was between 98.9 and 103%.,Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228411/),%,9,107572,DB01222,Budesonide
,25228411,total imprecision,"The quality control samples at concentration levels 200 and 2000 pg/mL gave a total imprecision of 7.4% and 4.2%, respectively, (n=95).",Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228411/),%,7.4,107573,DB01222,Budesonide
,25228411,total imprecision,"The quality control samples at concentration levels 200 and 2000 pg/mL gave a total imprecision of 7.4% and 4.2%, respectively, (n=95).",Phospholipid removal combined with a semi-automated 96-well SPE application for determination of budesonide in human plasma with LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228411/),%,4.2,107574,DB01222,Budesonide
,19203724,relative bioavailability,"Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide.",Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203724/),%,18,109370,DB01222,Budesonide
,19203724,relative bioavailability,"Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide.",Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203724/),%,36,109371,DB01222,Budesonide
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,152,118532,DB01222,Budesonide
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,240,118533,DB01222,Budesonide
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,165,118534,DB01222,Budesonide
,21233029,run time,The temperature of the autosampler was kept at 6 °C and the run time was 4.00 min.,Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233029/),min,4.00,120221,DB01222,Budesonide
,30174414,polydispersity index,"Dynamic light-scattering results showed that the particle size of budesonide-Eudragit S100/poly(lactic-co-glycolic acid) nanoparticles was around 110.5 nm, with a polydispersity index of 0.098.",Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30174414/),,0.098,123985,DB01222,Budesonide
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,3.07,136756,DB01222,Budesonide
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,6.21,136757,DB01222,Budesonide
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,0.84,136758,DB01222,Budesonide
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,1.50,136759,DB01222,Budesonide
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136760,DB01222,Budesonide
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136761,DB01222,Budesonide
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136762,DB01222,Budesonide
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136763,DB01222,Budesonide
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,15.5,136764,DB01222,Budesonide
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,50.8,136765,DB01222,Budesonide
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,4.41,136766,DB01222,Budesonide
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,12.78,136767,DB01222,Budesonide
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,1.08,136768,DB01222,Budesonide
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,0.09,136769,DB01222,Budesonide
,18357737,flow-rate,"Chromatographic separation was performed on a Capcell Pak C18 MG column with the mobile phase consisted of acetonitrile -5 mmol x L(-1) ammonium acetate (60:40, v/v) at a flow-rate of 0.50 mL x min(-1).",[LC-MS/MS determination of budesonide in dog plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357737/),[ml] / [min],0.50,139304,DB01222,Budesonide
,18357737,Cmax,"Maximal budesonide plasma level was observed after (3.5 +/- 3.3) h and the Cmax was (786 +/- 498) pg x mL(-1) after a single oral administration of 9 mg budesonide capsules, Cmax was increased to (2142 +/- 1515) pg x mL(-1) after multiple oral administration (9 mg x 5 d) of budesonide capsules.",[LC-MS/MS determination of budesonide in dog plasma]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357737/),[pg] / [ml],786,139305,DB01222,Budesonide
,18357737,Cmax,"Maximal budesonide plasma level was observed after (3.5 +/- 3.3) h and the Cmax was (786 +/- 498) pg x mL(-1) after a single oral administration of 9 mg budesonide capsules, Cmax was increased to (2142 +/- 1515) pg x mL(-1) after multiple oral administration (9 mg x 5 d) of budesonide capsules.",[LC-MS/MS determination of budesonide in dog plasma]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357737/),[pg] / [ml],2142,139306,DB01222,Budesonide
,17523699,clearance rate,"The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),[l] / [h],228,142575,DB01222,Budesonide
,17523699,protein binding fraction,Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%).,Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),%,98-99,142576,DB01222,Budesonide
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,332,142577,DB01222,Budesonide
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,183,142578,DB01222,Budesonide
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,1800,142579,DB01222,Budesonide
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,2200,142580,DB01222,Budesonide
,11762560,terminal half-life,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,3.5,145765,DB01222,Budesonide
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,3.9,145766,DB01222,Budesonide
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,10.1,145767,DB01222,Budesonide
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,12.0,145768,DB01222,Budesonide
,11762560,mean absorption times (MAT),"Using previously reported intravenous data, the mean absorption times (MAT) were calculated to be around 2 hours and 7 hours for BUD and FP respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,2,145769,DB01222,Budesonide
,11762560,mean absorption times (MAT),"Using previously reported intravenous data, the mean absorption times (MAT) were calculated to be around 2 hours and 7 hours for BUD and FP respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,7,145770,DB01222,Budesonide
,3549321,half-life,All pharmacokinetic parameters of the epimers differed except the half-life of about 1.5 h.,Pharmacokinetics of budesonide in children with asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549321/),h,1.5,155205,DB01222,Budesonide
,3549321,Plasma clearance,Plasma clearance averaged 103 l X h-1 for epimer 22 R and 74 l X h-1 for epimer 22 S; calculated per kg body weight these values were about 50% higher than in adults.,Pharmacokinetics of budesonide in children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549321/),[l] / [h],103,155206,DB01222,Budesonide
,3549321,Plasma clearance,Plasma clearance averaged 103 l X h-1 for epimer 22 R and 74 l X h-1 for epimer 22 S; calculated per kg body weight these values were about 50% higher than in adults.,Pharmacokinetics of budesonide in children with asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549321/),[l] / [h],74,155207,DB01222,Budesonide
,3549321,systemic availability,"The systemic availability of the aerosol was approximately 30% of nominal dose, i.e. the same as in adults.",Pharmacokinetics of budesonide in children with asthma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549321/),%,30,155208,DB01222,Budesonide
,31744668,flow rate,"Using testosterone as internal standard, the plasma samples were prepared by precipitation with acetonitrile and separated using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase composed of acetonitrile and 0.1 % (v/v) formic acid aqueous solution by gradient elution at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31744668/),[ml] / [min],0.3,155222,DB01222,Budesonide
,33152467,Cmax,The exception was that Cmax for glycopyrrolate was slightly lower in Asian versus Western subjects (0.6-0.7).,Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33152467/),,0.6-0.7,155773,DB01222,Budesonide
,10383539,systemic availability,"The mean [95% CI] systemic availability of budesonide with reference to the metered dose was: 13 [10; 15]%, 29 [23; 37]%, and 20 [16; 23]%, and the maximum plasma concentration (Cmax) was attained at (tmax) 2.0, 0.7, and 0.4 h after administration for the pressurized aerosol, aqueous pump spray, and powder, respectively.","Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383539/),%,13,160675,DB01222,Budesonide
,10383539,systemic availability,"The mean [95% CI] systemic availability of budesonide with reference to the metered dose was: 13 [10; 15]%, 29 [23; 37]%, and 20 [16; 23]%, and the maximum plasma concentration (Cmax) was attained at (tmax) 2.0, 0.7, and 0.4 h after administration for the pressurized aerosol, aqueous pump spray, and powder, respectively.","Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383539/),%,29,160676,DB01222,Budesonide
,10383539,systemic availability,"The mean [95% CI] systemic availability of budesonide with reference to the metered dose was: 13 [10; 15]%, 29 [23; 37]%, and 20 [16; 23]%, and the maximum plasma concentration (Cmax) was attained at (tmax) 2.0, 0.7, and 0.4 h after administration for the pressurized aerosol, aqueous pump spray, and powder, respectively.","Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383539/),%,20,160677,DB01222,Budesonide
,10383539,tmax,"The mean [95% CI] systemic availability of budesonide with reference to the metered dose was: 13 [10; 15]%, 29 [23; 37]%, and 20 [16; 23]%, and the maximum plasma concentration (Cmax) was attained at (tmax) 2.0, 0.7, and 0.4 h after administration for the pressurized aerosol, aqueous pump spray, and powder, respectively.","Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383539/),h,2.0,160678,DB01222,Budesonide
,10383539,tmax,"The mean [95% CI] systemic availability of budesonide with reference to the metered dose was: 13 [10; 15]%, 29 [23; 37]%, and 20 [16; 23]%, and the maximum plasma concentration (Cmax) was attained at (tmax) 2.0, 0.7, and 0.4 h after administration for the pressurized aerosol, aqueous pump spray, and powder, respectively.","Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383539/),h,0.7,160679,DB01222,Budesonide
,10383539,tmax,"The mean [95% CI] systemic availability of budesonide with reference to the metered dose was: 13 [10; 15]%, 29 [23; 37]%, and 20 [16; 23]%, and the maximum plasma concentration (Cmax) was attained at (tmax) 2.0, 0.7, and 0.4 h after administration for the pressurized aerosol, aqueous pump spray, and powder, respectively.","Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383539/),h,0.4,160680,DB01222,Budesonide
,16128685,serum C(max),"Systemic budesonide absorption was rapid and pharmacokinetic data were comparable with published data on marketed budesonide enemas, with mean serum C(max) and AUC(0-8 h) values of 0.8 +/- 0.5 ng/mL and 3.7 +/- 1.9 ng h/mL, respectively.",Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128685/),[ng] / [ml],0.8,162142,DB01222,Budesonide
,16128685,AUC(0-8 h),"Systemic budesonide absorption was rapid and pharmacokinetic data were comparable with published data on marketed budesonide enemas, with mean serum C(max) and AUC(0-8 h) values of 0.8 +/- 0.5 ng/mL and 3.7 +/- 1.9 ng h/mL, respectively.",Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16128685/),[h·ng] / [ml],3.7,162143,DB01222,Budesonide
,15676038,"AUC(0,infinity)","The mean AUC(0,infinity) value after Easyhaler treatment was 3.48 (standard deviation (SD) 0.93) ng ml(-1) h and after Turbuhaler treatment 3.46 (1.13) ng ml(-1) h.",Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676038/),[h·ng] / [ml],3.48,165443,DB01222,Budesonide
,15676038,"AUC(0,infinity)","The mean AUC(0,infinity) value after Easyhaler treatment was 3.48 (standard deviation (SD) 0.93) ng ml(-1) h and after Turbuhaler treatment 3.46 (1.13) ng ml(-1) h.",Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676038/),[h·ng] / [ml],3.46,165444,DB01222,Budesonide
,15676038,C(max),"The mean C(max) values (SD) for budesonide in plasma after Easyhaler and Turbuhaler treatments were 1.22 (0.41) ng ml(-1) and 1.29 (0.44) ng ml(-1), respectively.",Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676038/),[ng] / [ml],1.22,165445,DB01222,Budesonide
,15676038,C(max),"The mean C(max) values (SD) for budesonide in plasma after Easyhaler and Turbuhaler treatments were 1.22 (0.41) ng ml(-1) and 1.29 (0.44) ng ml(-1), respectively.",Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676038/),[ng] / [ml],1.29,165446,DB01222,Budesonide
,15676038,t(max),There was no statistically significant difference (P = 0.39) between the median t(max) for Easyhaler (30 min) and Turbuhaler treatment (23 min).,Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676038/),min,30,165447,DB01222,Budesonide
,15676038,t(max),There was no statistically significant difference (P = 0.39) between the median t(max) for Easyhaler (30 min) and Turbuhaler treatment (23 min).,Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676038/),min,23,165448,DB01222,Budesonide
,11475468,time to Cmax (tmax),"In patients with asthma (n = 38) receiving different doses of budesonide by DPI (Turbuhaler), the pharmacokinetic parameters peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) were dose-dependent after both single dose and repeat dose (3 weeks) administration: time to Cmax (tmax) was short (0.28 to 0.40 hours) and the elimination half-life approximately 3 hours.",Clinical pharmacokinetics of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475468/),h,0.28 to 0.40,173115,DB01222,Budesonide
,11475468,elimination half-life,"In patients with asthma (n = 38) receiving different doses of budesonide by DPI (Turbuhaler), the pharmacokinetic parameters peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) were dose-dependent after both single dose and repeat dose (3 weeks) administration: time to Cmax (tmax) was short (0.28 to 0.40 hours) and the elimination half-life approximately 3 hours.",Clinical pharmacokinetics of inhaled budesonide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475468/),h,3,173116,DB01222,Budesonide
,11475468,Cmax,"Mean model-independent parameters for (22R)-budesonide were as follows: Cmax 1.8 microg/L, tmax 0.46 hours, elimination half-life 2.3 hours and oral clearance 163 L/h, and there were no enantiomer-specific differences in drug disposition.",Clinical pharmacokinetics of inhaled budesonide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475468/),[μg] / [l],1.8,173117,DB01222,Budesonide
,11475468,tmax,"Mean model-independent parameters for (22R)-budesonide were as follows: Cmax 1.8 microg/L, tmax 0.46 hours, elimination half-life 2.3 hours and oral clearance 163 L/h, and there were no enantiomer-specific differences in drug disposition.",Clinical pharmacokinetics of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475468/),h,0.46,173118,DB01222,Budesonide
,11475468,elimination half-life,"Mean model-independent parameters for (22R)-budesonide were as follows: Cmax 1.8 microg/L, tmax 0.46 hours, elimination half-life 2.3 hours and oral clearance 163 L/h, and there were no enantiomer-specific differences in drug disposition.",Clinical pharmacokinetics of inhaled budesonide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475468/),h,2.3,173119,DB01222,Budesonide
,11475468,oral clearance,"Mean model-independent parameters for (22R)-budesonide were as follows: Cmax 1.8 microg/L, tmax 0.46 hours, elimination half-life 2.3 hours and oral clearance 163 L/h, and there were no enantiomer-specific differences in drug disposition.",Clinical pharmacokinetics of inhaled budesonide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475468/),[l] / [h],163,173120,DB01222,Budesonide
,11302946,half-life,"After inhalation, BUD half-life was longer (8.2 h) in trachea than in plasma (3.7 h), with similar data after intravenous dosing.",Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302946/),h,8.2,178649,DB01222,Budesonide
,11302946,half-life,"After inhalation, BUD half-life was longer (8.2 h) in trachea than in plasma (3.7 h), with similar data after intravenous dosing.",Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302946/),h,3.7,178650,DB01222,Budesonide
,11302946,half-life,BUD-oleate was formed in all tissues and had a longer half-life than BUD in trachea (18-20 h) but a similar half-life in plasma and muscle.,Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302946/),h,18-20,178651,DB01222,Budesonide
,11302946,selectivity,"After inhalation, the corresponding figures for selectivity were 10 and 50 to 1000, respectively.",Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302946/),,10,178652,DB01222,Budesonide
,11302946,selectivity,"After inhalation, the corresponding figures for selectivity were 10 and 50 to 1000, respectively.",Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302946/),,50 to 1000,178653,DB01222,Budesonide
,17825891,milk/plasma ratio,The mean milk/plasma ratio was 0.46.,Exposure of infants to budesonide through breast milk of asthmatic mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825891/),,0.46,179890,DB01222,Budesonide
,24433434,terminal half-life,"Ipilimumab PK was linear and time-invariant, with dose-proportional exposures over the available dose range, yielding a terminal half-life of approximately 15 days.",Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433434/),d,15,199407,DB01222,Budesonide
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1598.38,202225,DB01222,Budesonide
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1657.09,202226,DB01222,Budesonide
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1276.75,202227,DB01222,Budesonide
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],39.16,202228,DB01222,Budesonide
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],39.53,202229,DB01222,Budesonide
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],23.24,202230,DB01222,Budesonide
,31332649,time to peak FEV1 response,"The average time to peak FEV1 response was 3.94 h (standard deviation 2.75), while the standardized area under the response-time curve from 0 to 12 h for FEV1 was 2.72 (standard deviation 1.84).","Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332649/),h,3.94,210517,DB01222,Budesonide
,31332649,area under the response-time curve from 0 to 12 h,"The average time to peak FEV1 response was 3.94 h (standard deviation 2.75), while the standardized area under the response-time curve from 0 to 12 h for FEV1 was 2.72 (standard deviation 1.84).","Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332649/),,2.72,210518,DB01222,Budesonide
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB01222,Budesonide
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB01222,Budesonide
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB01222,Budesonide
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB01222,Budesonide
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB01222,Budesonide
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB01222,Budesonide
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB01222,Budesonide
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB01222,Budesonide
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB01222,Budesonide
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB01222,Budesonide
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB01222,Budesonide
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB01222,Budesonide
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB01222,Budesonide
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB01222,Budesonide
,1676668,plasma elimination half-life,"BUD was rapidly absorbed from the lung, and its plasma elimination half-life was about 3 hr.","Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676668/),h,3,215887,DB01222,Budesonide
,1676668,oral bioavailability,"Assuming that BDP was transformed entirely into BMP, the oral bioavailability of BMP at 1.5 mg/kg was around 72%, while that of BUD was 15%.","Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676668/),%,72,215888,DB01222,Budesonide
,1676668,oral bioavailability,"Assuming that BDP was transformed entirely into BMP, the oral bioavailability of BMP at 1.5 mg/kg was around 72%, while that of BUD was 15%.","Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676668/),%,15,215889,DB01222,Budesonide
,23416292,flow rate,"Baseline separation was obtained within 7min on an Acquity UPLC BEH C18 (50mm×2.1mm, 1.7μm) column using an isocratic mobile phase consisting of acetonitrile/5mM ammonium acetate/acetic acid (29:71:0.142, v/v/v) at a flow rate of 0.7mL/min.",Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry: application in a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23416292/),[ml] / [min],0.7,218268,DB01222,Budesonide
,23416292,ratio of total body clearance,"Consistent differences in the pharmacokinetics of the 22R and 22S epimers were observed, the AUC(0-∞) of 22S-BUD was approximately six times higher than that of 22R-BUD, and the 22S-/22R-BUD ratio of total body clearance was 0.17.",Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry: application in a stereoselective pharmacokinetic study. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23416292/),,0.17,218269,DB01222,Budesonide
,20884303,overall recovery,"An efficient solid-phase extraction (SPE) procedure for plasma samples yielded extremely clean extracts with overall recovery of 104.3% and 95.7% for triamcinolone acetonide (TA) and fluticasone propionate, respectively.",Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20884303/),%,104.3,221211,DB01222,Budesonide
,20884303,overall recovery,"An efficient solid-phase extraction (SPE) procedure for plasma samples yielded extremely clean extracts with overall recovery of 104.3% and 95.7% for triamcinolone acetonide (TA) and fluticasone propionate, respectively.",Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20884303/),%,95.7,221212,DB01222,Budesonide
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,39,221734,DB01222,Budesonide
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,13,221735,DB01222,Budesonide
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,21,221736,DB01222,Budesonide
,18623040,AUC ratios,Study II: AUC ratios were 97.9% (budesonide) and 82.2% (formoterol) (budesonide/formoterol pMDI versus budesonide pMDI+formoterol DPI).,"Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18623040/),%,97.9,224437,DB01222,Budesonide
,18623040,AUC ratios,Study II: AUC ratios were 97.9% (budesonide) and 82.2% (formoterol) (budesonide/formoterol pMDI versus budesonide pMDI+formoterol DPI).,"Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18623040/),%,82.2,224438,DB01222,Budesonide
,15355126,systemic availability,A low systemic availability of 9-21% indicates extensive first-pass elimination.,Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355126/),%,9-21,227652,DB01222,Budesonide
,12386638,terminal half-life,"The mean terminal half-life of budesonide was prolonged from 1.6 to 6.2 hours (ie, 3.7-fold; range, 1.5-fold to 9.3-fold; P <.001) by itraconazole.",Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386638/),h,1.6 to 6.2,227770,DB01222,Budesonide
,2332564,Time to relapse,"Time to relapse was longer with inhaled than with oral BUD (medians, 22 versus 7.9 days; p = 0.003) or placebo (medians, 22 versus 9 days; p = 0.004).",A study of the mechanism of the antiasthmatic action of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332564/),d,22,230887,DB01222,Budesonide
,2332564,Time to relapse,"Time to relapse was longer with inhaled than with oral BUD (medians, 22 versus 7.9 days; p = 0.003) or placebo (medians, 22 versus 9 days; p = 0.004).",A study of the mechanism of the antiasthmatic action of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332564/),d,7.9,230888,DB01222,Budesonide
,2332564,Time to relapse,"Time to relapse was longer with inhaled than with oral BUD (medians, 22 versus 7.9 days; p = 0.003) or placebo (medians, 22 versus 9 days; p = 0.004).",A study of the mechanism of the antiasthmatic action of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332564/),d,9,230889,DB01222,Budesonide
,32678687,viscosities,The viscosities for low and HV formulations were ∼5 and 50 cP.,"Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),cp,∼5,232920,DB01222,Budesonide
,32678687,viscosities,The viscosities for low and HV formulations were ∼5 and 50 cP.,"Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),cp,50,232921,DB01222,Budesonide
,32678687,Cmax,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),[μg] / [g],0.22,232922,DB01222,Budesonide
,32678687,Cmax,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),[μg] / [g],0.31,232923,DB01222,Budesonide
,32678687,tmax,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),h,0.67,232924,DB01222,Budesonide
,32678687,tmax,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),h,0.60,232925,DB01222,Budesonide
,32678687,tmax,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),h,0.53,232926,DB01222,Budesonide
,32678687,AUC0-6h,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),[h·μg] / [g],0.72,232927,DB01222,Budesonide
,32678687,AUC0-6h,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),[h·μg] / [g],0.53,232928,DB01222,Budesonide
,32678687,AUC0-6h,"The geometric mean budesonide Cmax values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, tmax values were 0.67, 0.60 and 0.53 h, and AUC0-6h values were 0.72, 0.53, and 0.95 μg h/g, respectively.","Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32678687/),[h·μg] / [g],0.95,232929,DB01222,Budesonide
,10510140,FEV1,"Mean FEV1 at inclusion was 3.4, 4.0 and 3.9 l min-1 in the three groups, respectively.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[l] / [min],3.4,234790,DB01222,Budesonide
,10510140,FEV1,"Mean FEV1 at inclusion was 3.4, 4.0 and 3.9 l min-1 in the three groups, respectively.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[l] / [min],4.0,234791,DB01222,Budesonide
,10510140,FEV1,"Mean FEV1 at inclusion was 3.4, 4.0 and 3.9 l min-1 in the three groups, respectively.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[l] / [min],3.9,234792,DB01222,Budesonide
,10510140,time to peak budesonide plasma concentration (tmax ),Mean time to peak budesonide plasma concentration (tmax ) was short (0.28-0.40 h) and did not differ between treatment groups.,Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),h,0.28-0.40,234793,DB01222,Budesonide
,10510140,half-life,"Budesonide concentrations declined rapidly thereafter, indicating efficient pulmonary absorption and rapid elimination with a half-life of approximately 3 h.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),h,3,234794,DB01222,Budesonide
,10510140,Cmax,"Cmax was 1. 4(2.0) nmol l-1 (single (repeated) doses), 2.6(3.6) nmol l-1 and 5. 4(6.4) nmol l-1 after 400, 800 and 1600 microg twice daily, respectively.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[nM] / [l],1. 4,234795,DB01222,Budesonide
,10510140,Cmax,"Cmax was 1. 4(2.0) nmol l-1 (single (repeated) doses), 2.6(3.6) nmol l-1 and 5. 4(6.4) nmol l-1 after 400, 800 and 1600 microg twice daily, respectively.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[nM] / [l],2.6,234796,DB01222,Budesonide
,10510140,Cmax,"Cmax was 1. 4(2.0) nmol l-1 (single (repeated) doses), 2.6(3.6) nmol l-1 and 5. 4(6.4) nmol l-1 after 400, 800 and 1600 microg twice daily, respectively.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[nM] / [l],5. 4,234797,DB01222,Budesonide
,10510140,area under the plasma concentration vs time curve (AUC),"The corresponding results for the area under the plasma concentration vs time curve (AUC) were 271(325), 490(628) and 915(1096) nmol l-1 min.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[min·nM] / [l],271,234798,DB01222,Budesonide
,10510140,area under the plasma concentration vs time curve (AUC),"The corresponding results for the area under the plasma concentration vs time curve (AUC) were 271(325), 490(628) and 915(1096) nmol l-1 min.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[min·nM] / [l],490,234799,DB01222,Budesonide
,10510140,area under the plasma concentration vs time curve (AUC),"The corresponding results for the area under the plasma concentration vs time curve (AUC) were 271(325), 490(628) and 915(1096) nmol l-1 min.",Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510140/),[min·nM] / [l],915,234800,DB01222,Budesonide
,12830002,peak plasma concentrations,Patients with PBC stage IV showed significantly higher peak plasma concentrations (4.9 +/- 3.5 vs.,Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,4.9,238429,DB01222,Budesonide
,12830002,areas under the plasma concentration-time curves (AUC),1.5 +/- 0.4 ng/mL; P <.05) and areas under the plasma concentration-time curves (AUC) (23.2 +/- 16.8 vs.,Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,23.2,238430,DB01222,Budesonide
,12830002,AUC,"Equally, AUC of budesonide were significantly increased under a multiple dose regimen on day 21 (14.0 +/- 11.6 vs.",Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,14.0,238431,DB01222,Budesonide
,31841699,accumulation ratio,"In the phase I PK study (30 patients), budesonide and glycopyrronium Cmax were comparable after single and chronic dosing of BGF MDI (accumulation ratio [RAC] 95% and 107%, respectively) whereas Cmax for formoterol was slightly higher after chronic dosing (RAC 116%).",Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841699/),%,95,243682,DB01222,Budesonide
,31841699,accumulation ratio,"In the phase I PK study (30 patients), budesonide and glycopyrronium Cmax were comparable after single and chronic dosing of BGF MDI (accumulation ratio [RAC] 95% and 107%, respectively) whereas Cmax for formoterol was slightly higher after chronic dosing (RAC 116%).",Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841699/),%,107,243683,DB01222,Budesonide
,8218754,Maximal plasma concentration (Cmax),Maximal plasma concentration (Cmax) of budesonide was 2.1 nmol/L 1.3 h after the first dose and 2.5 nmol/L 1.2 h after the last dose; the difference was not significant.,Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218754/),[nM] / [l],2.1,245668,DB01222,Budesonide
,8218754,Maximal plasma concentration (Cmax),Maximal plasma concentration (Cmax) of budesonide was 2.1 nmol/L 1.3 h after the first dose and 2.5 nmol/L 1.2 h after the last dose; the difference was not significant.,Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218754/),[nM] / [l],2.5,245669,DB01222,Budesonide
,8218754,area under the curve (AUC),The area under the curve (AUC) of plasma concentration vs. time was after the first dose 9.7 nmol h/L and after the last dose 11.6 nmol h/L (P < 0.03).,Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218754/),[h·nM] / [l],9.7,245670,DB01222,Budesonide
,8218754,area under the curve (AUC),The area under the curve (AUC) of plasma concentration vs. time was after the first dose 9.7 nmol h/L and after the last dose 11.6 nmol h/L (P < 0.03).,Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218754/),[h·nM] / [l],11.6,245671,DB01222,Budesonide
,9114906,area under the time vs plasma concentration curve 0-4 h,3. The plasma concentrations of budesonide were significantly reduced by the charcoal treatment (P < 0.01) and the area under the time vs plasma concentration curve 0-4 h was significantly reduced from 9.5 to 8.0 mmol l-1 h for 22S (P < 0.01) and from 7.6 to 5.7 mmol l-1 h for 22R (P < 0.01).,The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114906/),[h·mM] / [l],9,248551,DB01222,Budesonide
,9114906,area under the time vs plasma concentration curve 0-4 h,3. The plasma concentrations of budesonide were significantly reduced by the charcoal treatment (P < 0.01) and the area under the time vs plasma concentration curve 0-4 h was significantly reduced from 9.5 to 8.0 mmol l-1 h for 22S (P < 0.01) and from 7.6 to 5.7 mmol l-1 h for 22R (P < 0.01).,The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9114906/),[h·mM] / [l],7.6 to 5.7,248552,DB01222,Budesonide
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,8.6,253862,DB01222,Budesonide
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,10.7,253863,DB01222,Budesonide
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,527.0,253864,DB01222,Budesonide
,16697169,relative drug availability,"Furthermore, the relative drug availability obtained from the pharmacokinetic evaluation, expressed as the percentage of pulmonary absorption of the comparator product, was 154% and 220% for M and PB, respectively.",Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697169/),%,154,255056,DB01222,Budesonide
,16697169,relative drug availability,"Furthermore, the relative drug availability obtained from the pharmacokinetic evaluation, expressed as the percentage of pulmonary absorption of the comparator product, was 154% and 220% for M and PB, respectively.",Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16697169/),%,220,255057,DB01222,Budesonide
,11136277,systemic availability,"Average systemic availability of budesonide during fasting conditions was 10.7%, area under the curve was 27.5 nmol/L x h and peak plasma concentration was 4.1 nmol/L.",Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136277/),%,10.7,255244,DB01222,Budesonide
,11136277,area under the curve,"Average systemic availability of budesonide during fasting conditions was 10.7%, area under the curve was 27.5 nmol/L x h and peak plasma concentration was 4.1 nmol/L.",Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136277/),[nM] / [h·l],27.5,255245,DB01222,Budesonide
,11136277,peak plasma concentration,"Average systemic availability of budesonide during fasting conditions was 10.7%, area under the curve was 27.5 nmol/L x h and peak plasma concentration was 4.1 nmol/L.",Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136277/),[nM] / [l],4.1,255246,DB01222,Budesonide
,11136277,mean absorption time,Food increased the mean absorption time from 4.5 to 6.8 h (P=0.0012).,Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136277/),h,4.5,255247,DB01222,Budesonide
,11136277,mean absorption time,Food increased the mean absorption time from 4.5 to 6.8 h (P=0.0012).,Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136277/),h,6.8,255248,DB01222,Budesonide
,6958498,plasma half-life,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),h,2.8,266547,DB01222,Budesonide
,6958498,distribution volume,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),1,301.3,266548,DB01222,Budesonide
,6958498,plasma clearance,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),[1] / [h],83.7,266549,DB01222,Budesonide
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,10.7,266550,DB01222,Budesonide
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,72.8,266551,DB01222,Budesonide
,22538054,Bioavailability,Bioavailability of budesonide without inhibition was 27(12-42)%.,Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),%,27,267650,DB01222,Budesonide
,22538054,bioavailability,"At the two highest doses (128 mg and above) bioavailability approached 100%, showing that budesonide was completely absorbed from jejunum.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),%,100,267651,DB01222,Budesonide
,22538054,extraction ratios,"Applying sigmoid E(max)-models of the mean inhibitions in mucosa and liver indicated that, in this study performed under fed conditions, their uninhibited extraction ratios of budesonide were approximately 0.32 and 0.60, respectively.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),,0.32,267652,DB01222,Budesonide
,22538054,extraction ratios,"Applying sigmoid E(max)-models of the mean inhibitions in mucosa and liver indicated that, in this study performed under fed conditions, their uninhibited extraction ratios of budesonide were approximately 0.32 and 0.60, respectively.",Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538054/),,0.60,267653,DB01222,Budesonide
,16422998,AUC(0-infinity),"Pharmacokinetic parameters of budesonide following single-dose administration (e.g. AUC(0-infinity) 7.7+/-5.1 h ng/mL, C(max) 1.8+/-1.2 ng/mL) did not change upon multiple dosing.",Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16422998/),[h·ng] / [ml],7.7,268408,DB01222,Budesonide
,16422998,C(max),"Pharmacokinetic parameters of budesonide following single-dose administration (e.g. AUC(0-infinity) 7.7+/-5.1 h ng/mL, C(max) 1.8+/-1.2 ng/mL) did not change upon multiple dosing.",Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16422998/),[ng] / [ml],1.8,268409,DB01222,Budesonide
,26416605,AUCinf,"For the remaining 5 premature lambs, a non-compartmental analysis demonstrated an AUCinf of 148.77 ± 28.16 h*μg/L, half-life of 4.76 ± 1.79 h, and Cmax of 46.17 ± 17.71 µg/L.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),[h·μg] / [l],148.77,271264,DB01222,Budesonide
,26416605,half-life,"For the remaining 5 premature lambs, a non-compartmental analysis demonstrated an AUCinf of 148.77 ± 28.16 h*μg/L, half-life of 4.76 ± 1.79 h, and Cmax of 46.17 ± 17.71 µg/L.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),h,4.76,271265,DB01222,Budesonide
,26416605,Cmax,"For the remaining 5 premature lambs, a non-compartmental analysis demonstrated an AUCinf of 148.77 ± 28.16 h*μg/L, half-life of 4.76 ± 1.79 h, and Cmax of 46.17 ± 17.71 µg/L.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),[μg] / [l],46.17,271266,DB01222,Budesonide
,26416605,apparent clearance,"The apparent clearance and apparent volume of distribution of budesonide were estimated at 6.29 L/h (1.99 L/h/kg) and 29.1 L (9.2 L/kg), respectively.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),[l] / [h],6.29,271267,DB01222,Budesonide
,26416605,apparent volume of distribution,"The apparent clearance and apparent volume of distribution of budesonide were estimated at 6.29 L/h (1.99 L/h/kg) and 29.1 L (9.2 L/kg), respectively.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),l,29.1,271268,DB01222,Budesonide
,19649711,aerodynamic diameter,"Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 microm and 2.56, 1.75, and 2.54, respectively.","Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),μm,2.75,273529,DB01222,Budesonide
,19649711,aerodynamic diameter,"Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 microm and 2.56, 1.75, and 2.54, respectively.","Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),μm,4.60,273530,DB01222,Budesonide
,19649711,aerodynamic diameter,"Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 microm and 2.56, 1.75, and 2.54, respectively.","Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),μm,4.30,273531,DB01222,Budesonide
,19649711,aerodynamic diameter,"Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 microm and 2.56, 1.75, and 2.54, respectively.","Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),,2.56,273532,DB01222,Budesonide
,19649711,aerodynamic diameter,"Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 microm and 2.56, 1.75, and 2.54, respectively.","Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),,1.75,273533,DB01222,Budesonide
,19649711,aerodynamic diameter,"Mass median aerodynamic diameter and geometric standard deviation for conventional, microspheres, and porous particles formulations were 2.75, 4.60, and 4.30 microm and 2.56, 1.75, and 2.54, respectively.","Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),,2.54,273534,DB01222,Budesonide
,19649711,T(1/2),Estimates of relative bioavailability suggested that developed formulations have excellent lung deposition characteristics with extended T(1/2) from 9.4 to 14 h compared to conventional formulation.,"Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19649711/),h,9.4,273535,DB01222,Budesonide
,18786624,T(max),"T(max) was significantly (p<0.05) earlier for UDB 0.06, 0.12, and 0.24 mg (4.5+/-3.3, 3.1+/-1.5, 3.7+/-1.5 min) vs. commercial budesonide (9.1+/-7.1 min).",Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),min,4.5,274203,DB01222,Budesonide
,18786624,T(max),"T(max) was significantly (p<0.05) earlier for UDB 0.06, 0.12, and 0.24 mg (4.5+/-3.3, 3.1+/-1.5, 3.7+/-1.5 min) vs. commercial budesonide (9.1+/-7.1 min).",Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),min,3.1,274204,DB01222,Budesonide
,18786624,T(max),"T(max) was significantly (p<0.05) earlier for UDB 0.06, 0.12, and 0.24 mg (4.5+/-3.3, 3.1+/-1.5, 3.7+/-1.5 min) vs. commercial budesonide (9.1+/-7.1 min).",Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),min,3.7,274205,DB01222,Budesonide
,18786624,T(max),"T(max) was significantly (p<0.05) earlier for UDB 0.06, 0.12, and 0.24 mg (4.5+/-3.3, 3.1+/-1.5, 3.7+/-1.5 min) vs. commercial budesonide (9.1+/-7.1 min).",Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),min,9.1,274206,DB01222,Budesonide
,18786624,C(max),C(max) was significantly (p<0.05) higher for UDB 0.24 mg vs. commercial budesonide 0.25 mg (434.5+/-246.9 pg/mL vs. 303.5+/-177.4 pg/mL) but not between UDB 0.12 mg (239.9+/-140 pg/mL) and commercial budesonide 0.25 mg (p=0.448).,Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),[pg] / [ml],434.5,274207,DB01222,Budesonide
,18786624,C(max),C(max) was significantly (p<0.05) higher for UDB 0.24 mg vs. commercial budesonide 0.25 mg (434.5+/-246.9 pg/mL vs. 303.5+/-177.4 pg/mL) but not between UDB 0.12 mg (239.9+/-140 pg/mL) and commercial budesonide 0.25 mg (p=0.448).,Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),[pg] / [ml],303.5,274208,DB01222,Budesonide
,18786624,C(max),C(max) was significantly (p<0.05) higher for UDB 0.24 mg vs. commercial budesonide 0.25 mg (434.5+/-246.9 pg/mL vs. 303.5+/-177.4 pg/mL) but not between UDB 0.12 mg (239.9+/-140 pg/mL) and commercial budesonide 0.25 mg (p=0.448).,Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18786624/),[pg] / [ml],239.9,274209,DB01222,Budesonide
